Escolar Documentos
Profissional Documentos
Cultura Documentos
Chest 2003;123;221S-225S
DOI 10.1378/chest.123.1_suppl.221S
The online version of this article, along with updated information and
services can be found online on the World Wide Web at:
http://chestjournal.chestpubs.org/content/123/1_suppl/221S.full.html
Stage IIIB includes patients with T4, any N, M0, and any T, N3, M0. Surgery may be indicated
only for carefully selected T4N0M0 patients with or without neoadjuvant chemotherapy or
chemoradiotherapy. Patients with N3 lymph node involvement are not considered as surgical
candidates. For patients with unresectable disease, good performance score, and minimal weight
loss, treatment with combined chemotherapy and radiotherapy has resulted in better survival
than treatment with radiotherapy alone. Multiple daily fractions of radiotherapy have not
resulted in improved survival compared with standard fractionation once daily. Concurrent
chemoradiotherapy appears to be associated with improved survival compared with sequential
chemotherapy and radiotherapy. Treatment of stage IIIB due to malignant pleural effusion is
addressed in the section that deals with stage IV disease. (CHEST 2003; 123:221S–225S)
Key words: NSCLC stage IIIB; stage IIIB; unresectable lung cancer; unresectable NSCLC
S mors,
tage IIIB disease includes patients with T4 tu-
any N, M0, and any T, N3, M0. It is
Limited Role of Surgery
The 5-year survival of patients with clinically
estimated that 10 –15% of all patients are stage IIIB
at the time of diagnosis. The treatment options staged IIIB non-small cell lung cancer (NSCLC) is
depend on the extent of disease and include surgery 3 to 7%.1 Data on pathologically staged IIIB disease
alone in carefully selected patients or a combination was not available in the new Mountain International
of chemotherapy and radiotherapy. Surgical resec- Classification. Stage IIIB disease includes T4N0 –
tion after induction therapy may be appropriate in 3M0 and T1– 4N3M0. This section will not address
selected patients. Radiotherapy alone has been used treatment of patients with T4 disease due to malig-
in the past but should be limited to patients with nant pleural or pericardial effusions or IIIB Pancoast
poor performance score. Chemotherapy alone is not tumors. Malignant effusions will be addressed in the
a good treatment option except for patients with section on stage IV disease, and Pancoast tumors will
malignant pleural effusion (discussed in the section be discussed in the chapter on special treatment
on stage IV disease). issues.
Surgery may be indicated for stage IIIB disease
Methods only in carefully selected situations.2 Patients who
are T4N0 –1 due solely to a satellite tumor nodule(s)
This section of the evidence-based guidelines is within the primary tumor lobe have a 5-year survival
based on an extensive review of the medical litera- of approximately 20% with surgery alone.3,4 Individ-
ture, including 8 guidelines, 5 meta-analyses, and 20 uals with T4N0 –1 disease due to main carinal in-
manuscripts and abstracts, with an emphasis on volvement have been treated with carinal resection
phase III randomized control trials. Selected key with or without pulmonary resection. Carinal resec-
references are included in the bibliography. tion carries an appreciable mortality of 10 to 15%,
with an increased risk of local recurrence.5,6 The
*From the Mayo Clinic (Dr. Jett), Rochester, MN; Section of 5-year survival in these carefully selected series is
Thoracic Surgical Oncology, Fox Chase Cancer Center (Dr.
Scott), Philadelphia, PA; University of North Carolina (Dr. approximately 20%.
Rivera), Chapel Hill, NC; LDS Hospital, University of Utah Neoadjuvant chemotherapy, or chemoradiother-
(Dr. Sause), Salt Lake City, UT. apy followed by surgical resection, has been used in
Correspondence to: James R. Jett, MD, FCCP, Mayo Clinic, 200
First Street Southwest, Rochester, MN 55905; e-mail: jett.james@ patients with N2 (IIIA) disease. However, few phase
mayo.edu II series have included carefully selected patients